Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer

MT Newswires Live06-25

Aprea Therapeutics (APRE) said Wednesday that initial data from a phase 1 trial showed that APR-1051 achieved "early disease control" with a 5% tumor reduction at the first radiographic assessment of a patient with advanced human papillomavirus-positive head and neck squamous cell carcinoma, or HNSCC.

The investigational therapy was also well-tolerated, with no dose-limiting toxicities, the company said, adding the trial is actively enrolling more HPV+ patients and moving into higher dose levels.

Aprea also said preclinical data generated through an ongoing research collaboration with MD Anderson Cancer Center showed that APR-1051 has potential both as a standalone therapy and in combination with immunotherapy for biomarker-driven treatment of HPV+ HNSCC.

APR-1051 showed "robust" antiproliferative effects across a wide range of human and mouse head and neck cancer cell lines, including HPV+ subtypes, according to the company. When combined with anti-PD-1 immunotherapies, APR-1051 demonstrated "significant" anti-tumor synergy, Aprea added.

Shares of Aprea were up 1.2% in recent trading.

Price: 1.66, Change: +0.02, Percent Change: +1.22

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2546241017?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-25 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546241017","market":"sh","top_or_hot":-1,"title":"Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer","media":"MT Newswires Live","content":"<html><body><p> Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (APRE) said Wednesday that initial data from a phase 1 trial showed that APR-1051 achieved \"early disease control\" with a 5% tumor reduction at the first radiographic assessment of a patient with advanced human papillomavirus-positive head and neck squamous cell carcinoma, or HNSCC.</p><p>The investigational therapy was also well-tolerated, with no dose-limiting toxicities, the company said, adding the trial is actively enrolling more HPV+ patients and moving into higher dose levels.</p><p>Aprea also said preclinical data generated through an ongoing research collaboration with MD Anderson Cancer Center showed that APR-1051 has potential both as a standalone therapy and in combination with immunotherapy for biomarker-driven treatment of HPV+ HNSCC.</p><p>APR-1051 showed \"robust\" antiproliferative effects across a wide range of human and mouse head and neck cancer cell lines, including HPV+ subtypes, according to the company. When combined with anti-PD-1 immunotherapies, APR-1051 demonstrated \"significant\" anti-tumor synergy, Aprea added.</p><p>Shares of Aprea were up 1.2% in recent trading.</p><p>Price: 1.66, Change: +0.02, Percent Change: +1.22</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-25 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (APRE) said Wednesday that initial data from a phase 1 trial showed that APR-1051 achieved \"early disease control\" with a 5% tumor reduction at the first radiographic assessment of a patient with advanced human papillomavirus-positive head and neck squamous cell carcinoma, or HNSCC.</p><p>The investigational therapy was also well-tolerated, with no dose-limiting toxicities, the company said, adding the trial is actively enrolling more HPV+ patients and moving into higher dose levels.</p><p>Aprea also said preclinical data generated through an ongoing research collaboration with MD Anderson Cancer Center showed that APR-1051 has potential both as a standalone therapy and in combination with immunotherapy for biomarker-driven treatment of HPV+ HNSCC.</p><p>APR-1051 showed \"robust\" antiproliferative effects across a wide range of human and mouse head and neck cancer cell lines, including HPV+ subtypes, according to the company. When combined with anti-PD-1 immunotherapies, APR-1051 demonstrated \"significant\" anti-tumor synergy, Aprea added.</p><p>Shares of Aprea were up 1.2% in recent trading.</p><p>Price: 1.66, Change: +0.02, Percent Change: +1.22</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2546241017","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546241017","pubTimestamp":1750864583,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Aprea Therapeutics  said Wednesday that initial data from a phase 1 trial showed that APR-1051 achieved \"early disease control\" with a 5% tumor reduction at the first radiographic assessment of a patient with advanced human papillomavirus-positive head and neck squamous cell carcinoma, or HNSCC.The investigational therapy was also well-tolerated, with no dose-limiting toxicities, the company said, adding the trial is actively enrolling more HPV+ patients and moving into higher dose levels.Aprea also said preclinical data generated through an ongoing research collaboration with MD Anderson Cancer Center showed that APR-1051 has potential both as a standalone therapy and in combination with immunotherapy for biomarker-driven treatment of HPV+ HNSCC.APR-1051 showed \"robust\" antiproliferative effects across a wide range of human and mouse head and neck cancer cell lines, including HPV+ subtypes, according to the company. When combined with anti-PD-1 immunotherapies, APR-1051 demonstrated \"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APRE":"Aprea Therapeutics, Inc."},"translate_title":"Aprea称APR-1051显示HPV阳性头颈癌的早期疾病控制","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APRE":0.9},"content_text":"Aprea Therapeutics (APRE) said Wednesday that initial data from a phase 1 trial showed that APR-1051 achieved \"early disease control\" with a 5% tumor reduction at the first radiographic assessment of a patient with advanced human papillomavirus-positive head and neck squamous cell carcinoma, or HNSCC.The investigational therapy was also well-tolerated, with no dose-limiting toxicities, the company said, adding the trial is actively enrolling more HPV+ patients and moving into higher dose levels.Aprea also said preclinical data generated through an ongoing research collaboration with MD Anderson Cancer Center showed that APR-1051 has potential both as a standalone therapy and in combination with immunotherapy for biomarker-driven treatment of HPV+ HNSCC.APR-1051 showed \"robust\" antiproliferative effects across a wide range of human and mouse head and neck cancer cell lines, including HPV+ subtypes, according to the company. When combined with anti-PD-1 immunotherapies, APR-1051 demonstrated \"significant\" anti-tumor synergy, Aprea added.Shares of Aprea were up 1.2% in recent trading.Price: 1.66, Change: +0.02, Percent Change: +1.22","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546241017","isCrawlerRequest":true}